TY - JOUR
T1 - L-type amino acid transporter 1 deficiency delays intestinal tissue repair in dextran sulfate sodium-induced colitis
AU - Sui, Yunlong
AU - Okamoto, Norihiro
AU - Hoshi, Namiko
AU - Inoue, Yuta
AU - Ku, Yuna
AU - Agawa, Misaki
AU - Nakamura, Hirotaka
AU - Miyazaki, Haruka
AU - Watanabe, Daisuke
AU - Ooi, Makoto
AU - Yano, Yoshihiko
AU - Ohgaki, Ryuichi
AU - Kanai, Yoshikatsu
AU - Yang, Hui
AU - Kodama, Yuzo
N1 - Publisher Copyright:
© 2025 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license. http://creativecommons.org/licenses/by/4.0/
PY - 2026/3/1
Y1 - 2026/3/1
N2 - Background: Inflammatory bowel disease (IBD) remains a public health concern, with increasing incidence and prevalence globally. L-type amino acid transporter 1 (LAT1) has been reported to be upregulated during the active phase of ulcerative colitis; however, its role in the course of colitis remains unclear. In this study, we aimed to explore the role of LAT1 in colitis. Methods: Mice with intestinal epithelium-specific deletions of LAT1 (LAT1fl/fl; vil-cre) were treated with dextran sulfate sodium (DSS) to investigate its role in colitis. Organoids derived from these mice were also analyzed. Results: LAT1 expression was significantly upregulated in DSS-induced colitis. LAT1fl/fl; vil-cre mice did not show increased susceptibility during DSS-induced colitis but exhibited more severe injury following DSS treatment. Its deficiency did not significantly influence inflammatory cytokine gene expression and epithelial proliferation or apoptosis. However, during the tissue repair phase, LAT1fl/fl; vil-cre mice showed a reduced number of colonic crypts and Hes-1 gene expression. Accordingly, organoids derived from LAT1-deficient crypts exhibited a markedly reduced capacity for colonic organoid formation. Conclusions: LAT1 deficiency in the intestinal epithelium delays tissue repair by impairing colonic crypt regeneration. Our findings offer insights into how nutrient availability in the tissue environment is sensed by cells and may influence the control of colonic tissue recovery from inflammatory damage.
AB - Background: Inflammatory bowel disease (IBD) remains a public health concern, with increasing incidence and prevalence globally. L-type amino acid transporter 1 (LAT1) has been reported to be upregulated during the active phase of ulcerative colitis; however, its role in the course of colitis remains unclear. In this study, we aimed to explore the role of LAT1 in colitis. Methods: Mice with intestinal epithelium-specific deletions of LAT1 (LAT1fl/fl; vil-cre) were treated with dextran sulfate sodium (DSS) to investigate its role in colitis. Organoids derived from these mice were also analyzed. Results: LAT1 expression was significantly upregulated in DSS-induced colitis. LAT1fl/fl; vil-cre mice did not show increased susceptibility during DSS-induced colitis but exhibited more severe injury following DSS treatment. Its deficiency did not significantly influence inflammatory cytokine gene expression and epithelial proliferation or apoptosis. However, during the tissue repair phase, LAT1fl/fl; vil-cre mice showed a reduced number of colonic crypts and Hes-1 gene expression. Accordingly, organoids derived from LAT1-deficient crypts exhibited a markedly reduced capacity for colonic organoid formation. Conclusions: LAT1 deficiency in the intestinal epithelium delays tissue repair by impairing colonic crypt regeneration. Our findings offer insights into how nutrient availability in the tissue environment is sensed by cells and may influence the control of colonic tissue recovery from inflammatory damage.
KW - Colitis
KW - Inflammatory bowel disease
KW - L-type amino acid transporter 1
KW - Tissue repair
UR - https://www.scopus.com/pages/publications/105029098252
UR - https://www.scopus.com/pages/publications/105029098252#tab=citedBy
U2 - 10.1016/j.intimp.2025.116138
DO - 10.1016/j.intimp.2025.116138
M3 - Article
C2 - 41519003
AN - SCOPUS:105029098252
SN - 1567-5769
VL - 172
JO - International Immunopharmacology
JF - International Immunopharmacology
M1 - 116138
ER -